Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Hyloris Pharmaceuticals SA
  6. Summary
    HYL   BE0974363955

HYLORIS PHARMACEUTICALS SA

(HYL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
07/23/2021 07/26/2021 07/27/2021 07/28/2021 07/29/2021 Date
13.1(c) 13.35(c) 13.8(c) 13.75(c) 13.65 Last
7 308 1 516 4 699 2 137 894 Volume
-1.87% +1.91% +3.37% -0.36% -0.73% Change
More quotes
Estimated financial data (e)
Sales 2020 0,95 M 1,13 M 1,13 M
Net income 2020 -6,00 M -7,13 M -7,13 M
Net cash position 2020 48,0 M 57,0 M 57,0 M
P/E ratio 2020 -8,04x
Yield 2020 -
Sales 2021 3,65 M 4,34 M 4,34 M
Net income 2021 -12,0 M -14,3 M -14,3 M
Net cash position 2021 43,0 M 51,1 M 51,1 M
P/E ratio 2021 -29,3x
Yield 2021 -
Capitalization 355 M 419 M 422 M
EV / Sales 2020 323x
EV / Sales 2021 85,5x
Nbr of Employees -
Free-Float 40,6%
More Financials
Company
Hyloris Pharmaceuticals is a Belgium-based specialty pharmaceutical company. Its focus is on re-engineering cardiovascular products. Additionally, it also further develops and improves already-approved pharmaceuticals and established products, creating new and different solutions. The CompanyÔÇÖs diverse product-development portfolio spans a wide range of therapeutic indications and dosage forms. 
Sector
Pharmaceuticals
Calendar
08/04Earnings Release
More about the company
All news about HYLORIS PHARMACEUTICALS SA
07/27HYLORIS PHARMACEUTICALS : to Report 2021 Half-Year Results on 4 August 2021
AQ
07/08HYLORIS PHARMACEUTICALS : Starts Selling Non-Opioid Painkiller in Germany, Austr..
MT
07/08Hyloris Pharmaceuticals Sa Launches Maxigesic IV
CI
06/26Certain Warrants of Hyloris Pharmaceuticals SA are subject to a Lock-Up Agree..
CI
06/26Certain Subscription Rights of Hyloris Pharmaceuticals SA are subject to a Lo..
CI
06/24Hyloris Successfully Renegotiates License Agreements for Lead Products with t..
CI
06/08HYLORIS PHARMACEUTICALS SA : Proxy Statments
CO
05/07HYLORIS PHARMACEUTICALS SA : Mixed general shareholder meeting
CO
05/06HYLORIS PHARMACEUTICALS : Extends Maxigesic IV Licensing Deal to 17 Latin Americ..
MT
05/06Hyloris Announces Extension of Footprint of Maxigesic« IV into South America
GL
04/28Hyloris Pharmaceuticals SA Announces Major Commercial Partnership in the U.S...
CI
03/09Hyloris Pharmaceuticals SA Reports Consolidated Earnings Results for the Year..
CI
03/09HYLORIS PHARMACEUTICALS SA : Annual results
CO
02/05Hyloris and Purna Female Healthcare Announce Partnership to Develop Novel Wom..
CI
02/05Purna Female Healthcare announced that it expects to receive Ç4.3 million in ..
CI
More news
News in other languages on HYLORIS PHARMACEUTICALS SA
07/27Hyloris publiera ses résultats semestriels 2021 le 4 août 2021
07/08Hyloris lanceert pijnstiller Maxigesic op Duitse markt
07/08Hyloris annonce le lancement de Maxigesic« IV, un nouveau traitement de la do..
06/24Hyloris heronderhandelt met succes over licentieovereenkomsten
06/24Hyloris renégocie avec succès les accords de licence pour les produits phares..
More news
Chart HYLORIS PHARMACEUTICALS SA
Duration : Period :
Hyloris Pharmaceuticals SA Technical Analysis Chart | HYL | BE0974363955 | MarketScreener
Technical analysis trends HYLORIS PHARMACEUTICALS SA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 13,75 €
Average target price 16,50 €
Spread / Average Target 20,0%
EPS Revisions
Managers and Directors
Stijn van Rompay Chief Executive Officer, CFO & Executive Director
Stefan Yee Chairman
Dietmar Aichhorn Chief Operating Officer
Marc Foidart Independent Director
Carolyn J. Myers Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HYLORIS PHARMACEUTICALS SA44.74%419
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%332 374
PFIZER, INC.18.04%243 220
ELI LILLY AND COMPANY46.00%224 084
NOVARTIS AG0.39%223 750